Phase II trial of Dasatinib monotherapy for Philadelphia positive acute lymphoblastic leukemia in the Elderly
Not Applicable
- Conditions
- Philadelphia positive acutelymphoblastic leukemia
- Registration Number
- JPRN-UMIN000007736
- Lead Sponsor
- Study group of DASPAL-E
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
1. active double cancer 2. uncontrollable complication 3. past history of TKI/chemotherapy 4. physicians' decision
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Event free survival rate at 1 year
- Secondary Outcome Measures
Name Time Method